| Name | Allitinib |
| Description | Allitinib (AST-1306) (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1] |
| In vitro | AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) inhibits the growth of HIH3T3-EGFR T790M/L858R cells[1]. AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families[1]. In A549, Calu-3, and SK-OV-3 cells, AST1306 inhibits tyrosine kinase activation and downstream signaling pathways, and dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells[1]. |
| In vivo | AST1306 (AST-1306; oral; 25-100 mg/kg) significantly inhibited tumor growth in SK-OV-3 and Calu-3 xenograft models[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (122.53 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.46 mM), Sonication is recommended.
|
| Keywords | Irreversible | Inhibitor | inhibit | HER1 | ErbB4 | ErbB2 | ErbB-1 | Epidermal growth factor receptor | EGFRL858R/T790M | EGFR (T790M/L858R) | EGFR | AST1306 | AST 1306 | anti-cancer | anilino-quinazoline | ALS-1306 | ALS1306 | Allitinib |
| Inhibitors Related | (S)-Afatinib | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Chalcone | Brigatinib | Genistein | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
